To the Editor:
Langerhans cell histiocytosis (LCH) has been described as an inflammatory myeloid neoplasia that affects various organs. CNS involvement may result in endocrinopathies and progressive neurodegeneration (ND-LCH), characterized by low-grade inflammation and degenerative changes, resulting in cognitive deficits, behavioral disturbances and neuromotor dysfunction. 1 Prolonged disease activity is a risk factor for ND-LCH. 1 Potential biomarkers in cerebrospinal fluid (CSF) indicative of ND-LCH have been suggested (e.g. neurofilament protein light chain; NF-L), 2 while increased interleukin(IL)-17A levels in blood and extracranial lesions of LCH patients have been associated with local and systemic inflammation. 3, 4 Independently, IL-17A
has been shown to disrupt the blood-brain-barrier and increase production of reactive oxygen species in brain endothelial cells, pointing towards a crucial step for the development of experimental autoimmune encephalitis 5 and possibly also for ND-
LCH.
There is currently no established therapy for ND-LCH, although many have been proposed. [6] [7] [8] [9] We aimed to find an effective therapy for a child with severe, rapidly progressive ND-LCH unresponsive to standard treatments. The patient was followed clinically (for >15 years), by MRI and by measuring NF-L in the CSF and later also IL-17A in CSF and plasma.
Briefly, the patient was diagnosed with LCH at five months of age, which rapidly progressed into multisystem LCH with risk-organ involvement. Following initial treatment (LCH-II protocol) she stabilized but after several reactivations she developed a chronic active disease with elevated erythrocyte sedimentation rate (ESR). At four years of age, clinical signs of ND were noted (tripping, clumsiness) and brain MRI a year later revealed widespread ND-LCH affecting the basal ganglia, corpus callosum, cerebellum and medulla. Despite many treatments, the patient deteriorated markedly within the next four years. Prompted by the need for effective treatment, at the age of eight years we initiated granulocyte-and-monocyte-apheresis (GMA), initially in parallel with conventional LCH treatment (Figure 1 ; at week 0), aiming at removing activated granulocytes and monocytes, thus reducing the inflammatory load. 10 GMA was initially performed weekly for ten weeks, followed by clinical improvement, decreased NF-L and regression of cerebellar lesions. After a ten-week break, GMA was restarted and performed every second week (eleven sessions). During a subsequent four-month break, higher NF-L levels were noted and GMA was restarted but performed less frequently and with less noticeable benefits. Therefore, her treatment was replaced with a combination of vinblastine and simvastatin (without GMA) to benefit from the anti-inflammatory effect of simvastatin. However, the patient deteriorated the following six months with more fatigue, impaired balance and gait, and increased NF-L ( Figure 1A) . Nystagmus was confirmed a few months later. Given the positive effects of the first GMA treatments, GMA was restarted (w115).
Cytarabine was given in parallel for six months based on positive reports from others.
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Due to absence of clinical improvement, lack of alternative treatment and considering the positive effects of natalizumab on patients with multiple sclerosis (MS), 12 we then administered natalizumab after thorough discussions with neurologists and the parents. Figure   1A ). Due to lack of improvement and increased risk of progressive multifocal leukoencephalopathy with prolonged treatment, natalizumab was ceased.
Attracted by the lack of side-effects from GMA in this patient who had not responded to other treatments, GMA was now (w220) intensified to once weekly in parallel to low corticosteroid pulses (initially every 2w, later every 3-4w) for more than two years. NF-L decreased during this period, and the neurological deterioration eventually slowed down; the patient stabilized clinically and MRI remained stable. In addition, but most apparent initially, positive effects were noted on the patient's fatigue, possibly due to the marked decrease in circulating cytokine levels ( Figures 1B-G Although LCH pathogenesis remains unclear, increased IL-17A production has been associated with higher disease activity. 3, 4 Our observation that high IL-17A levels in blood and CSF accompany the disease progression supports a possible role for IL-17A
in ND-LCH pathogenesis. Notably, when IL-17A levels decreased, NF-L levels also decreased and the patient's fatigue improved. Measurement of IL-17A plasma levels in three additional LCH patients described to have isolated CNS involvement also revealed significantly increased IL-17A plasma levels (394, 369 and 234 pg/ml, with corresponding ESR of 3, 5, and 26 mm/hr, respectively) compared to 28 controls (median IL-17A: 120 pg/ml, p<0.01, Mann-Whitney). In line, high IL-17A and IL-23 levels have been reported in serum and CSF of patients with amyotrophic lateral sclerosis, a progressive neurodegenerative disease.
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Only a few children with either acute relapse of MS, neuromyelitis optica or acute disseminated encephalomyelitis have been reported to receive short-term apheresis
14 Recently, short-term GMA has also been beneficial in sarcoidosis. 15 To the best of our knowledge, our study is the first in which GMA has been used regularly for long-term (>6 years) and, importantly, without major side-effects. The treatment removed cytokine-producing cells from blood and decreased the levels of IL-17A in plasma and CSF. Possibly, the number of cytokine-producing cells in tissues was also reduced. 16 Since various treatments were administered and the natural development of the neurodegenerative process is not well known, where some patients stabilize with age, we cannot be certain if, and if so to what extent, GMA contributed to the stabilization of our patient. Nevertheless, our study suggests that (long-term) GMA may be considered for experimental treatment in patients with systemic LCH, aiming to reduce hypercytokinemia and disease activity. Finally, our novel finding that IL-17A may be used as an additional CSF biomarker for ND-LCH provides an additional method for detecting and monitoring ND-LCH. For
